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TRAINING AND ORTHOTIC EFFECTS RELATED TO FUNCTIONAL ELECTRICAL 
STIMULATION OF THE PERONEAL NERVE IN STROKE*
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Objective: To examine the evidence for a training ef-
fect on the lower limb of functional electrical stimu-
lation. 
Design: Cohort study.
Patients: A total of 133 patients >6 months post-
stroke.
Methods: Training and orthotic effects were deter-
mined from walking speed over 10 m, associated 
minimal and substantial clinically important diffe-
rences (i.e. >0.05 and >0.10 m/s), and Functional 
Ambulation Category (FAC), ranging from household 
walking to independent walking in the community.
Results: An overall significant (p < 0.01) training ef-
fect was found that was not a clinically important 
difference (0.02 m/s); however, “community” FAC 
(≥ 0.8 m/s) and “most limited community walkers” 
FAC (0.4–0.58 m/s), but not “household walkers” 
(< 0.4 m/s), benefitted from a clinically important 
difference. A highly significant (p< 0.001), substan-
tial clinically important orthotic effect (0.10 m/s) 
was found. In terms of overall improvement of one 
or more FACs, 23% achieved this due to a training 
effect, compared with 43% due to an orthotic effect.
Conclusion: The findings suggest that functional 
electrical stimulation provides a training effect in 
those who are less impaired. Further work, which 
optimizes the use of the device for restoration of 
function, rather than as an orthotic device, will pro-
vide greater clarity on the effectiveness of functional 
electrical stimulation for eliciting a training effect.
Key words: electrical stimulation; peroneal nerve; stroke; 
long-term training effect; therapeutic effect; temporary car-
ry-over effect; walking speed; foot drop.
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Functional electrical stimulation (FES) of the pero-neal nerve seeks to restore a normal walking pat-
tern in those with drop foot, which is characterized by 
weakness or paralysis leading to an inability to activate 
the dorsiflexor muscles. An “orthotic effect” describes 
the immediate improvement in walking observed with 
FES compared with that without FES. A “training or 
therapeutic effect” describes a long-term improvement 
in walking without the FES after using FES for several 
weeks. In contrast, a “temporary carry-over effect” is 
experienced as an immediate, short-term improvement 
in function, following a brief period of using FES, 
which lasts up to 1 h (1–3). A close association has 
been found between peroneal nerve stimulation and 
an increase in excitatory synapses in the brain (2–4), 
suggesting that a carry-over effect may be associated 
with a long-term training effect. However, the identifi-
cation of a long-term training effect is complicated by 
the potential presence of a temporary carry-over effect. 
Therefore, researchers attempting to measure a long-
term training effect may be misled by the presence of 
a short-term carry-over effect, temporarily increasing 
the speed of walking.
A number of studies have found evidence for a train-
ing effect of FES, ranging between 0.06 and 0.18 m/s 
using the timed 10-m walking test (10MWT) (5–8). It 
is unclear from these studies how much of the observed 
improvement can be attributed to a stable long-term 
training effect, which would be present without FES, 
as there have been no studies of the impact of a tem-
porary carry-over effect. Furthermore, the temporary 
carry-over effect may also mask any benefits due to 
the orthotic effect, as temporarily increasing unassisted 
walking speed would reduce the size of the difference 
compared with walking with FES. A masking of the 
true orthotic effect is of particular interest when inter-
preting previous research (6, 8–10) that has examined 
the differences between FES and other orthotic devi-
ces, as the measurement protocol may have led to an 
underestimation of the benefits of FES. One method 
to more reliably measure a long-term training effect 
is to maintain a set order of walking with the non-
stimulated measurement being made first. A further 
issue with using the 10MWT as a measurement is 
that it includes 3 walks without and 3 walks with the 
assistance of FES, requiring a distance of 60 m to be 
covered. Studies that have measured FES use in this 
way (6, 7, 9, 10) are not representative of the FES user 
population who are unable to complete this distance.
A further limitation of some studies is to neglect the 
impact of the first 6 months post-stroke (6–8), which is 
when most spontaneous recovery is commonly repor-
ted to occur (11, 12). Therefore, any benefits observed 
*Some of the data from this study was presented at the UK Stroke 
Conference on 2–4 December 2014, in Harrogate, UK. 
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114 T. Street et al.
could be due to the usual neuroplastic changes that 
occur after insult to the brain. 
The current study examined the existence of a long-
term training effect of FES in patients more than 6 
months after stroke using an adapted 10MWT protocol 
to minimize any temporary carry-over effect. 
METHODS
Participants 
A total of 133 participants, > 6 months post-stroke (53 females, 
80 males, mean age 59 years, age range 8–87 years, median time 
post-stroke 2.7 years, range 29 weeks to 34 years) with a drop 
foot, formed a referred sample for treatment (Fig. 1). A sample 
of convenience was used in the study, with participants being 
referred on an outpatient basis to the FES clinic by either general 
practitioners or hospital consultants. The majority were funded 
by the UK’s National Health Service (NHS). All patients seen 
between 2008 and 2015 who met the study inclusion criteria 
were included in the study. Analysis was conducted using rou-
tine audit data collected at each appointment; therefore ethical 
approval was not required. The study conforms to the principles 
of the Declaration of Helsinki. 
Seventeen participants had previously used and rejected an 
ankle-foot orthosis (AFO). The main reason for rejection was 
due to the AFO not helping with walking. Twenty-seven parti-
cipants were currently using an AFO at the start of treatment. 
Exclusion criteria were: patients less than 6 months post-
stroke at the start of treatment; inability to walk 10 m even with 
the assistance of a walking aid; poorly controlled epilepsy; fixed 
skeletal deformities; recent injury; fracture; surgery; major skin 
conditions; proximity of cancerous tissue to the site of stimula-
tion. Subjects with a cardiac pacemaker, implanted defibrillator 
or other active implanted device were investigated by a cardiac 
technician to ensure that there was no interaction with FES. 
Clinical procedure
After an initial assessment to determine whether FES was a 
suitable treatment for use as a daily walking aid, patients were 
invited to return for 2 set-up appointments. At the first appoint-
ment they were instructed how to use the FES equipment. FES 
was applied using 2 electrodes placed over the common peroneal 
nerve either at the head of the fibula or popliteal fossa and over 
the motor point of the tibialis anterior. Stimulation was timed 
to the swing phase of gait using a foot switch under the heel, 
causing dorsiflexion with a small degree of eversion. Patients 
were instructed to gradually introduce the device into their 
everyday walking to become accustomed to the stimulation as 
an orthotic device. Patients were encouraged to use the device 
whenever they felt it would assist their walking. No further 
instructions were given as to the duration and frequency with 
which participants should use the device. Patients used the 
ODFS PACE (single channel) (Odstock Medical Ltd, Salisbury, 
UK). All devices stimulated at 40 Hz using either a symmetrical 
or asymmetrical biphasic waveform, with current intensity up 
to 100 mA and pulse width up to 360 ms. Stimulation, intensity, 
waveform, and timing parameters were adjusted to optimize the 
correction of drop foot for each individual.
All measurements were taken at baseline and again after a 
median of 20 weeks (interquartile range (IQR) 19–20 weeks). 
Timed 10MWT was measured using 3 different walks. The first 
walk was unassisted and used as a “warm-up”, the second mea-
sured unassisted walking, and the third was used as a measure 
of the effect of FES. A fourth walk measured unassisted walking 
following the use of FES immediately after the preceding walks, 
to determine whether there was a temporary carry-over effect 
from using FES. 
Walking speed was measured in order to determine any long-
term training effect, orthotic effect and temporary carry-over 
effect. An initial orthotic effect was defined as the difference 
between walking with no stimulation and walking with stimu-
lation at baseline. A continuing orthotic effect measured the 
difference between no stimulation and stimulation at follow-
up. A total orthotic effect measured the difference between no 
stimulation at baseline and stimulation at follow-up. A long-
term training effect was measured as the difference between 
no stimulation at baseline and no stimulation at follow-up, to 
ascertain whether use of the device for 20 weeks had led to 
measurable improvements when it was switched off. A tem-
porary carry-over effect was measured as a check, to ensure that 
the benefit observed from a long-term training effect, was not 
simply due to a temporary carry-over. It was not expected that 
temporary carry-over effect would be statistically significant. 
A temporary carry-over effect was calculated as the difference 
between unassisted walking after 20 weeks immediately prior 
to the FES walk and compared with the unassisted walk im-
mediately after the FES walk. 
Clinically important differences in 10MWT were defined as 
a substantial clinically important difference (≥ 0.10 m/s) or a 
minimal clinically important difference (≥ 0.05 to < 0.10 m/s) 
(13). FAC were also derived from unassisted walking speed, 
ranging from household walking to independent walking in the 
community (< 0.4 m/s = household walking only, 0.4–0.58 m/s = 
most limited community walking, 0.59–0.79 m/s = least limited 
community walking, ≥ 0.8 m/s = community walking) (14). 
Fig. 1. Flow of patients through the study. FES: functional electrical 
stimulation.
 
 
 
 
 
 
 
 
 
 
 
 
 
Assessed for eligibility (n=156) 
Excluded (n=23) 
Unable to complete protocol 
(started FES treatment with 
exercise only
Started FES treatment 
(n=133) 
Discharged from treatment (n=9) 
• Memory cognitive difficulties (n=2) 
• Funding (n=2) 
• Spasms in legs (n=1) 
• Chiropody issues painful to walk (n=2) 
• Too much inconvenience (n=2) 
 
Analysed (n=104) 
Excluded from analysis (n=20) 
Data not collected: 
• Due to persistent cancellations from poor 
health (n=4) 
• Insufficient clinic time at baseline (n=13) 
• Fatigue at baseline (n=1) 
• Measurement interrupted at baseline (2) 
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115Effects of FES of the peroneal nerve in stroke
Speed of walking without using FES measured on day 1 was 
used to define initial Functional Ambulation Category (FAC) 
of each participant prior to using FES. In addition, clinically 
important differences were used to examine the effect of FES 
on patients in the highest and lowest FAC. The measures were 
included to determine whether there was a difference in the 
clinically meaningful effects of FES on 10MWT in those in the 
lowest FAC compared with the highest FAC (14). 
Clinical observations were recorded at baseline and follow-
up. These included life events unrelated to FES, such as a back 
operation requiring bed rest, and adverse events related to the 
device, such as skin irritation. They also included technical is-
sues that the patient encountered with the device itself, which 
required repair, as well as technical issues that the patient en-
countered while using the device, such as a difficulty in finding 
the optimum electrode position. Anything that had led to the 
patient not using the device regularly in the 20-week period of 
the study, such as a hospital stay for 2 weeks, a technical fault 
that required repair, and patient-reported frequency of FES 
use per week, was recorded as “infrequent use” of FES. Other 
clinical observations that may have had an impact on use of 
the device were recorded, such as cognitive issues, dysphasia, 
and whether the patient presented with complex mobility issues 
including spasticity and clonus. 
Data from the step-counter of the device were recorded for 
the total number of steps, walks and walk duration. These mea-
sures were only included for 35 users, as the software has only 
recently been developed to allow these measures to be recorded 
reliably. A step was measured from the end of the rising ramp to 
the point of heel strike on the affected limb, in order to prevent 
small movements that are not steps being measured (Fig. 2). 
A walk count is taken from the number of times that the pause 
function on the device is unpaused and the walk duration is the 
total time spent unpaused. Therefore, people who do not pause 
the device while sitting down will have longer walk durations. 
The FES device measured steps, walks and walk duration 
continuously for the 20-week period; therefore the number of 
steps, walks and walk duration per day was not available. To 
provide an estimate of the total number of steps per day, the 
total number of steps for the 20-week period was divided by 
the individual time period each person used FES. The same 
procedure was used to estimate the number of walks and walk 
duration per day for each person. 
Statistical analysis
Statistical analysis was performed using NCSS 9 statistical 
software (NCSS LLC, Utah, USA). Data were explored using 
histograms and box-plots and found not to be in a normal 
distribution. Planned comparisons were conducted using the 
Wilcoxon signed-rank test. A significance level of p < 0.05 was 
used. The Holm-Bonferroni Sequential correction was used 
to adjust for multiple comparisons. The planned comparisons 
included a long-term training effect, and initial, continuing and 
total orthotic effects, as described above. 
RESULTS
A total of 124 patients (93%) still used FES 20 weeks 
after the start of the study, with 104 complete data-sets 
being available for analysis. The most common reason 
for patients to be excluded from the analysis was insuf-
ficient clinic time at baseline to undertake the outcome 
measures (n = 13). Insufficient clinic time describes a 
lack of time available following the set-up of the FES 
device, which may be due to the presentation of the 
patient being more complex. Nine participants were 
discharged from treatment due to memory or cogni-
tive difficulties (n = 2), issues with funding (n = 2), 
chiropody issues making it painful to walk (n = 2), and 
finding FES to be too much inconvenience (n = 2). One 
participant discontinued treatment due to leg spasms; 
however, it is unclear whether the FES was linked to 
this occurrence. Nine patients experienced some degree 
of minor skin irritation from using the electrodes. This 
number was inconsistent with that found in individual 
clinical observations in each patient record (n = 16), 
therefore suggesting a lack of reporting. Thus, 12% 
of participants encountered some form of minor skin 
irritation, but in all cases clinical management enabled 
continued use of FES. Further clinical observations 
are provided below. The study included 2 participants 
with cardiac pacemakers, following the use of cardiac 
monitoring at the initial appointment, to ensure that 
there was no interaction with the FES device. The par-
ticipants experienced no adverse events, providing the 
first study to report on the safe use of FES for people 
with pacemakers. 
Timed 10-Metre Walking Test 
The main planned comparison of interest was training 
effect, which achieved a significant difference between 
unassisted walking speed on day 1 (0.50 m/s) compared 
with unassisted walking speed after using FES for 20 
weeks (0.53 m/s) (Z=2.64, p = 0.008); however, this 
difference was not clinically meaningful (median diffe-
rence 0.02 m/s, IQR 0.05–0.12) (Table I). A substantial 
clinically meaningful change (median difference 0.10 
m/s, IQR 0.02–0.20) was found for total orthotic effect 
between day 1 unassisted walking speed (0.50 m/s) 
compared with walking with FES after 20 weeks (0.64 
m/s) (Z=6.64, p = 0.001). An immediate initial orthotic 
benefit on day 1 and continuing orthotic effect after 
20 weeks were also found to be significant (Table I). 
Fig. 2. Stimulation envelope: a step is measured from the end of the 
rising ramp (the rising ramp starts at heel rise and is the adjustable 
gradual increase in the stimulation pulse width from zero to reach the 
set pulse width) to the point of heel strike. 
J Rehabil Med 49, 2017
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116 T. Street et al.
A temporary carry-over effect was measured as a 
check to ascertain whether the observed long-term 
training effect was inflated by a temporary improvement 
in unassisted walking. No significant difference was 
found between the median speed for walking unassisted 
prior to stimulation of 0.64 (SD 0.31) m/s and walking 
without stimulation 0.64 (SD 0.30) m/s (p = 0.73). The-
refore, this suggests that the long-term training effect 
had not been affected by a temporary carry-over effect.
Functional Ambulation Category and clinically 
important differences
Excluding the community FAC, which could not 
improve as it was the highest category, overall, 43% 
(32/75) of participants improved their speed by one-- 
FAC or more in terms of an orthotic effect and 23% 
(17/75) improved in terms of a training effect (Table 
II). Clinically important differences in training effect, 
according to FAC, were used to explore the data further 
(Table III). Community walkers in the least impaired 
category were found to benefit from a median clinically 
important difference in training effect (both 0.06 m/s). 
In contrast, household walkers, who were the most 
impaired walking category, appeared less likely to 
have a clinically important training effect (0.02 m/s). 
Overall, clinically important differences for each 
planned comparison revealed continuing orthotic ef-
fect to have the highest proportion of people 66 (64%) 
with a clinically important difference, whether it was 
substantial or minimal. Unassisted walking had the 
highest amount of decline, with 28 (27%) people ha-
ving a clinically important decline whether substantial 
or minimal (Fig. 3).
Clinical observations
The clinical observations are shown in Table IV. 
The most frequent clinical observation was “patient 
technical” issues of using the stimulator, of which 47 
issues were identified. These most frequently involved 
difficulty in positioning electrodes (n = 17), followed 
closely by poor electrode care (n = 15), i.e. allowing 
the electrodes to become dry and not changing them. 
The second most common clinical observation was 
“complex presentation” issues (n = 33), which included 
spasticity and clonus. Thirty-six percent (16/45) of par-
ticipants with a clinically important improvement had 
2 or more identified clinical observations, in contrast 
82% (27/33) of those who had a clinically important 
decline had 2 or more identified clinical observations. 
Similarly, 82% (23/28) of those who did not achieve 
a clinically meaningful improvement or decline had 2 
or more identified clinical observations. 
Step counter 
Step counter data recorded on the FES device was col-
lected to measure quantitatively the frequency of using 
the FES device (n = 35). The median number of steps 
per day was 813 (IQR 108–1,244 steps) (Table V). The 
Table II. Number of patients who improved or declined one 
Functional Ambulation Category or more for training and total 
orthotic effect
Walking category 
prior to FES (n)
Training effect 
Total orthotic 
effect
Improvement
n (%)
Decline
n (%)
Improvement
n (%)
Decline
n (%)
Household (38) 6 (16) N/A 12 (32) N/A
Most limited (20) 6 (30) 3 (15) 12 (60) 0
Least limited (17) 5 (29) 2 (12) 8 (47) 2 (12)
Community (29) N/A 6 (21) N/A 2 (7)
FES: functional electrical stimulation; N/A: not applicable to examining whether 
patients in the household category decreased or the community category 
increased. This is further examined using clinically important differences in 
FAC (Fig. 2). 
Table III. Frequency of patients according to Functional Ambulation 
Category who demonstrated a clinically important difference (> 0.05 
m/s) in training effect 
FAC 
(n)
Training effect 
Medians of the 
differences (IQR) 95% CI
Improvement
n (%)
Decline
n (%)
Household 
(38) 12 (32) 7 (18) 0.02 (–0.03–0.07) –0.02 to 0.04
Most limited 
(20) 11 (55) 6 (30) 0.06 (–0.05–0.12)* –0.05 to 0.12
Least limited 
(17) 8 (47) 4 (24) 0.04 (–0.03–0.11) –0.03 to 0.11
Community 
(29) 15 (52) 11 (38) 0.06 (–0.08–0.18)* –0.07 to 0.12
*Clinically important difference. 
FES: functional electrical stimulation; FAC: Functional Ambulation Category; 
CI: confidence intervals; n: number in each walking category at baseline 
prior to using FES.
Table I. Walking speed (m/s) for stroke patients with and without functional electrical stimulation (n=104) 
Planned comparison
Baseline After 20 weeks
Z-value p-value
Holm Bonferroni 
p-value correction
Medians of the 
difference IQR
Non-FES 
Median
 FES 
Median
Non-FES 
Median
FES 
Median
Initial orthotic effect 0.50 0.59 6.65 0.001 0.004 0.06* 0.01–0.09
Continuing orthotic effect 0.53 0.64 7.29 0.001 0.004 0.08* 0.01–0.13
Total orthotic effect 0.50 0.64 6.64 0.001 0.004 0.10** 0.02–0.20
Training effect 0.50 0.53 2.64 0.008 0.008 0.02 –0.05–0.12
*Minimal clinically important difference. **Substantial clinically important difference.
IQR: interquartile range; FES: functional electrical stimulation.
www.medicaljournals.se/jrm
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117Effects of FES of the peroneal nerve in stroke
number of steps per day, walks and duration of walking 
per day was further examined for those who benefitted 
from a clinically meaningful training effect (n = 16) and 
those who experienced a clinically important decline 
(n = 8). The data revealed that those who achieved a 
clinically important training effect walked with stimu-
lation for a longer duration of walking, walked more 
often, and took a greater number of steps (Table V). 
DISCUSSION
Evidence was found for a significant training effect for 
FES of the lower limb; however, this was not clinically 
important (0.02 m/s). Further exploration revealed a 
clinically important training effect in the least impaired 
community ambulation category (0.06 m/s). In cont-
rast, household walkers in the most impaired category 
did not gain a clinically important difference (0.02 
m/s). Nevertheless, household walkers achieved an 
overall substantially clinically important orthotic effect 
(0.10 m/s). These findings suggest that the main benefit 
of FES is likely to be an orthotic effect; however, FES 
may be associated with a long-term training effect in 
those who are less impaired.
The more impaired group may have been less likely 
to acquire a training effect due to less residual cortical 
function. The new protocol for measuring the 10MWT 
also enabled a greater number of more impaired wal-
kers to be included compared with previous work, 
potentially leading to an overall decrease in the size of 
the training effect. The results for less impaired walkers 
were consistent with the findings (0.06–0.08 m/s) of 
previous studies examining a training effect (5, 6, 8), 
suggesting that the reduced size of the training effect 
in the current study was influenced by the inclusion of 
a greater number of more impaired participants.
Table IV. Life events unrelated and related to functional electrical stimulation use and adverse events that may have had an impact on 
the use of functional electrical stimulation categorised by clinically important differences in training effect
Issue identified
≥ 0.10a 
(n = 31)
≥ 0.05 to 0.10b
(n = 14)
≤ –0.05 to 0.10c
(n = 17)
≤ –0.10d 
(n = 14)
< 0.05 to > –0.05e
(n = 28)
Total 
(n = 104)
No issues 16 0 0 1 2 19
Dysphasia 4 1 1 1 2 9
Skin irritation 3 6 0 1 5 15
Infrequent use 4 4 11 12 10 41
Complex presentationf 2 5 7 2 17 33
Patient technicalg 4 8 9 11 15 47
Unrelated illness 1 2 3 5 10 21
Fall 1 0 0 3 3 7
Technical fault 3 5 6 3 12 29
No notes 2 0 3 0 0 5
Mental health 1 0 4 1 1 7
Cognitive 1 3 3 1 3 11
Pain from electrodes 0 1 3 0 5 9
Fatigue 0 0 1 1 0 2
Total 42 35 51 42 85 255
aSubstantial improvement; bminimal improvement; cminimal decline; dsubstantial decline; enon-clinically important difference; fcomplex presentation – including 
spasticity and clonus; gpatient technical – including the patient having difficulty with correct placement of electrodes or poor care of electrodes.
Table V. Median and interquartile range (IQR) for total steps, 
walks and duration of walking (minutes) per day for those with a 
clinically important decline in unassisted walking speed (no training 
effect) (n = 8) and those with a clinically important improvement 
in walking speed (training effect) (n = 16)
Steps per daya
n (IQR)
Walks per dayb 
n (IQR)
Duration of 
walking min/day 
n (IQR)
All data (n = 35) 813 (108–1244) 2 (1–5) 29 (5–77)
Clinically important 
decline (n =8) 553 (197–1284) 3 (0–6) 22 (7–57)
Clinically important 
improvement (n =16) 878 (534–1276) 3 (2–14) 54 (24–125)
aA step is measured from the end of the rising ramp to the point of heel strike 
for one side of the body. For total median number of steps per day the figure 
is doubled (Fig. 3).
bWalk count is taken from the number of times that the pause function on the 
device is unpaused and the walk duration is the total time spent unpaused. 
Therefore people who don’t pause the device whilst sitting down will have 
longer walk durations. 
Fig. 3. Clinically important differences for improvement and decline 
in walking speed due to training effect (n = 104). Training effect is the 
difference between unassisted walking at baseline and at 20 weeks 
follow-up. Initial orthotic effect is the difference between unassisted 
walking and functional electrical stimulation (FES) on day 1. Continuing 
orthotic effect is the difference between unassisted walking and walking 
with FES at follow-up. Total orthotic effect is the difference between 
unassisted walking on day 1 and FES walking at follow-up.
J Rehabil Med 49, 2017
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118 T. Street et al.
non-stimulated walk prior to using stimulation. Ho-
wever, similarly to previous studies, patients are likely 
to have walked to their follow-up appointment using 
FES,  therefore potentially eliciting a temporary carry 
over effect despite the new protocol. Further work is 
therefore required to examine the presence, duration 
and size of any observed temporary carry-over effects.
Conclusion
FES for foot drop may be associated with a long-term 
training effect in less impaired stroke patients. Studies 
designed to optimize rehabilitation potential rather than 
an orthotic effect, would provide greater clarity on the 
effectiveness of FES for eliciting long-term changes 
in walking ability. A potential area for further research 
is the intensity of FES treatment through using step 
counters, which enable a daily record of use to be do-
cumented. A greater understanding of the temporary 
carry-over effect may provide greater insight into the 
mechanism behind any long-term training effects and 
may enable rehabilitation specialists to enhance the 
size of the long-term training effect. 
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